Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.00−0.08 (-0.44%)
Close on Nov 17, 2026Market cap $2.88BP/E –Yield –
Denali Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Denali Therapeutics's pe ratio was 141.2× on Jan 31, 2022.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2022 | Jan 31, 2022 | 141.2× | −42.8 |
| 2021 | Dec 31, 2021 | 184.1× | – |
See a number that looks wrong?